This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
KaloBios Pharmaceuticals, Inc. [KBIO], a biopharmaceutical company dedicated to improving the lives of seriously ill patients with difficult-to-treat diseases through a portfolio of proprietary, patient-targeted, first-in-class monoclonal antibodies (mAbs), will visit the NASDAQ MarketSite in Times Square.
In honor of the occasion,
David Pritchard, President & CEO, will ring the Closing Bell.
NASDAQ MarketSite – 4 Times Square – 43
rd & Broadway – Broadcast Studio
Tuesday, March 12, 2013 – 3:45 p.m. to 4:00 p.m. ET
Joan E. Kureczka Kureczka/Martin Associates Tel: (415) 821-2413 Mobile: (415) 690-0210
Consuelo Alatorre KaloBios Pharmaceuticals, Inc. Tel: (650) 243-3120 Mobile: (650) 278-6805
Jen Knapp (212) 401-8916
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
Facebook and Twitter:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at:
For news tweets, please visit our Twitter page at:
A live webcast of the NASDAQ Closing Bell will be available at:
To obtain a hi-resolution photograph of the Market Close, please go to
http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.
About KaloBios Pharmaceuticals, Inc. [KBIO]:
KaloBios Pharmaceuticals, Inc. is developing a portfolio of proprietary, patient-targeted, first-in-class monoclonal antibodies (mAbs) designed to significantly improve the lives of seriously ill patients with difficult-to-treat diseases.